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Abstract
Milk is a major source of dietary energy, protein and fat. Due to their specific biological
properties leading to health benefits, bioactive peptides (BAPs) derived from milk pro‐
teins have been a subject of intensive research during past two decades. These peptide
sequences, encrypted within proteins, are liberated in vivo during gastrointestinal di‐
gestion or in vitro by fermentation with proteolytic starter cultures or using proteases.
BAP generally comprises 2–20 amino acid (AA) residues. Isolation and characterization
of BAP of different bioactivities from milk protein hydrolysates of cow, buffalo, camel,
goat, mare, sheep, donkey and yak milks have been reported. Bioactivities of BAP, which
depend on constituent AAs and the sequence, include mineral binding, opioid, angio‐
tensin-converting enzyme (ACE) inhibition, immunomodulatory, cytotoxicity, antibac‐
terial  and  antithrombotic.  This  chapter  focuses  on  the  methodologies  adopted  to
produce BAPs and their prospective role in health enhancing nutraceuticals/pharma‐
ceuticals.
Keywords: bioactive peptides, bioactivities, casein, milk proteins, nutraceuticals,
whey
1. Introduction
One of the achievements of mankind over a century is the remarkable progress in the field of
healthcare  including  management  of  communicable  diseases  leading  to  increase  in  life
expectancy of population around the world. However, there is a tremendous upsurge in non-
communicable diseases (NCDs) such as cardiovascular diseases (CVDs), diabetes, obesity, etc.,
which are associated more to life style changes and eating habits than to hereditary [1]. About
two-thirds of the 57 million deaths that occurred globally in 2008 were due to NCD [2]. Further
one-fourth of these deaths occurred before the age of 60. One among the four major behav‐
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ioural risk factors identified for NCD is unhealthy diet. Healthy diet and physical activity were
an integral part of the WHO’s 2008–2013 action plan of the global strategy for the preven‐
tion and control of NCDs. Essential nutrients, standards and guidelines for diet and food
preparation were considered prime for nutrition in the twentieth century [3]. New challeng‐
es now arise due to increased life expectancy, drastic life style modifications and elevated costs
of healthcare. This has directed to new nutritional concepts which target maximum well-being
and good health along with minimum disease risk throughout the lifespan. Nutraceuticals
and functional foods are an attempt towards resolving these health issues and to create a
healthy society [4]. The idea of nutraceuticals/functional foods is more often mentioned as an
emerging field. However, the concept has been well acknowledged in ancient Indian Vedic
texts and Chinese traditional medicine where it quotes “food and medicine have common
source.” Egyptians and Sumerians are just a few other civilizations that show evidence of food
being used as medicine and in disease prevention [5].
There is no agreement on the definition of nutraceutical and functional foods. The term
nutraceutical was first mentioned by Defelice in 1989 [6]. It was defined by Zeisel as “those
diet supplements that deliver a concentrated form of a presumed bioactive agent from a food,
presented in a non-food matrix and used to enhance health in dosages that exceed those that
could be obtained from normal foods” [7]. European Commission Concerted Action on
Functional Food Science in Europe (FUFOSE) originally proposed that a food can be consid‐
ered “functional” if it provides positive impact upon one or more physiological functions in
addition to its nutritional effects and improves health via reducing disease. Nutraceutical is
also defined as an isolated or purified product from food that is generally in medicinal form
and not generally related to food where as a functional food is defined as foods that offer more
than basic nutrition by providing additional physiological benefit [8]. The biological active
substances in functional foods (designer foods/medicinal or therapeutic foods) can either be
an essential macro/micronutrient, a non-nutritive component or a component whose nutri‐
tive value is not listed as essential [9]. Functional foods are generally grouped into conven‐
tional foods containing natural bioactive substances, enriched or modified foods with bioactive
substances and synthesised food. These foods as alone or in combination are considered
functional foods. Foods/food product could be prepared using different approaches to make
it functional: (a) by removing a component that may be identified to cause harmful effect when
consumed, (b) elevating a constituent naturally present to induce targeted effect, (c) introduc‐
ing a micro/macro nutrient for its positive effect and (d) substituting a constituent usually with
macronutrient or increasing bioavailability of a food component [5]. Japan was the first country
to emerge in production of functional foods to cope with accelerating cost of healthcare in 1980,
mainly to improve the health condition of the aging population [5, 10]. Scientific studies have
catered to the growing awareness on the relationship between nutrition and health issues that
have led the end users’ attention towards healthy foods. Functional or biologically active
molecules from food have been widely studied and assessed for moderating these condi‐
tions as well as to restore their normal physiological functioning.
Biopeptides from dietary proteins have exhibited potential benefits to intervene these
abnormal biophysiological conditions [11]. Bioactive peptides (BAPs) have been defined as
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protein fragments that have a progressive impact on body functions or conditions ultimately
influencing health [12]. When BAPs are encrypted within their parent proteins, they are
described as “cryptide” or a hidden peptide and are released by gastric digestion of food
proteins or by exogenous/endogenous proteolysis by plant, animal or microbial proteases
(especially during fermentation) [13]. These peptides demonstrate diverse physiological
functions including metabolic functions, immunomodulatory, microbicidal, thrombolytic and
pre/probiotic functions in human system [14]. Existing knowledge about milk-protein-derived
BAPs as pharmaceutical constituent for potent drug or dietary supplement in the form of
formulations of nutraceuticals is reviewed in detail in this chapter.
2. Sources of BAPs
Food proteins are not only a source of nutrients for maintenance of proper body functions but
are also considered as a source of BAPs which can promote health and prevent diseases. BAPs
are released from food proteins by endogenous proteolysis during gastric digestion or by
exogenous hydrolysis using physical (heat), chemical (acid/alkali) or plant/animal/microbial
proteases during food processing [15, 16]. Unlike physical/chemical treatments, enzymatic
hydrolysis has an advantage of producing intact BAPs without any residual/toxic chemicals
in the end products [17]. The size of active sequences may vary from 2 to 20 amino acid (AA)
residues and generally have molecular weight <6000 Da [18]. BAP from different sources are
found to possess common structural properties with hydrophobic AA residues in addition to
lysine, proline or arginine [19]. Low molecular weights (dimer–heptamer) of BAPs are resilient
to gastrointestinal (GI) tract enzymes and are easily absorbable in an intact form into the blood
stream, hence suitable for therapeutic formulations or as functional foods. Higher molecular
weight BAPs, in contrast, are possibly degraded during their passage through GI tract making
them either inactive or less active. However, in few cases they may also become more active
and thus more absorbable to be transported to target organs. Although milk proteins are
considered as the most important source for BAPs, animal, plant and marine proteins also
contain potential bioactive sequences [13, 20, 21].
2.1. Milk as a source of BAP
Milk is a characteristic secretion by female mammals with an array of bioactive substances to
meet whole nutritional requirements, defensive and physiological functions of the young ones
of that particular species. It is considered as one of the nearly complete single foods availa‐
ble in nature for maintaining human health and growth. Although the major mammalian milk
that is consumed by humans is that from bovine, milk from sheep, goats, yak, horses and
camels is also used. Constituents of milk are similar among species but differ significantly
between species [22]. Major constituents of milk include carbohydrates, proteins, lipids,
micronutrients and traces of various other organic and inorganic compounds. Lactose is the
key carbohydrate present in milk, which is a disaccharide formed from glucose and galac‐
tose with β 1-4 glycosidic linkage. Fat content of cow’s milk is ~3.25%. Bovine milk fat
composition is distinct from other sources due to their diet and the presence of a rumen.
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Normal bovine milk comprises about 3.5% of protein, 80% and 20% of which are constituted
by casein and whey proteins, respectively [23]. Sub-fractions of casein and whey possess
specific biological properties.
Milk from different animal sources, such as bovine, goat, yak and donkey, has been exten‐
sively studied for production of BAPs and for their potential positive impact on health, and
physiological benefits have been experimentally investigated [24]. Among these, cow’s milk
has proven to be the best source. To effectively produce biofunctional peptides, a combina‐
tion of such processes is also preferred [15]. Expression of dormant bioactivities of BAPs,
encrypted within the sequence of parent proteins, depends on the site of proteolysis, i.e., in
mammary gland or at a GI location as well as the specificity of proteases. Milk-protein-derived
BAPs have claimed to be health enhancing components that can be used to reduce the risk of
disease or to enhance a certain physiological function, such as potential antimicrobial,
antihypertensive, antioxidative, cytomodulary, immune stimulating, opiate effects, etc., in
humans. BAPs derived from milk protein may function as exogenous regulatory substances
at diverse intestinal and peripheral sites of mammals. They may be absorbed via carrier-
mediated or paracellular transport to regulate activities of target organs [12].
The primary physiological role of casein was considered to be a source of AAs required for
neonatal nutrition. However, subsequent studies have shed light on its diverse physiological
roles including prevention of pathological calcification of mammary gland by micellar
caseins [25]. It is a phosphoprotein that precipitates at 20°C from raw skimmed milk at pH 4.6.
The electrophoretic separation and AA sequence homology evaluations of different casein
fractions revealed its heterogeneous nature with four major families of casein: α1, α2, β and κ
[26]. Individual casein differs in the phosphate content and calcium-binding properties.
Generally, α1-, α2- and β-caseins bind calcium strongly and precipitate at relatively low calcium
concentrations and hence referred as “calcium-receptive caseins” having concentrated
phosphoserine and proline regions. In contrast, κ-casein is “non-receptive casein” (not
sensitive to these calcium concentrations), which can stabilise up to 10 times its mass of the
calcium-sensitive caseins and possesses one phosphoserine [27]. Caseins α1 and β have
potential to liberate more than 20,000 biofunctional peptides each. Biopeptide from casein was
the first identified food-derived BAP that boosted Vitamin D-independent bone calcification
in rachitic infants in 1950 [28]. Few milk-derived peptides reveal multi-functional properties,
i.e., specific peptide sequences having two or more different biological activities, as casein’s
primary structure possesses overlapping peptides or “strategic zones” in certain regions. These
zones are generally protected from proteases [29]. For example, a strategic zone containing
immuno-stimulating and opioid peptides has been reported to reside between residues 51–63
and 60–70 of human and bovine β-casein, respectively [30, 31].
Whey is the chief by-product or even considered as a co-product of cheese and other dairy
industries. Concentration of protein in whey depends on various factors, such as milk source,
time of the year, type of animal feed, lactation stage, processing quality and whey type [32].
Whey proteins constitute 20% of the whole milk protein, which are heterogeneous in nature.
Discovery of whey dates back to 3000 years ago. Seventeenth and eighteenth centuries
observed whey being used for its medicinal purpose [33]. Whey proteins are now consid‐
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ered as the highest quality natural protein available [34]. In recent past, there has been an
exponential research on whey proteins due to the presence of nutrients that are found to have
an active role in the betterment of human health [35, 36]. Whey proteins constitute 20% of
whole milk protein which are heterogeneous in nature. All whey proteins are soluble, perform
functions like carrier ligands and are involved in various biological activities. Elevated
nutritional values of whey proteins are attributed to their diverse AA composition [15].
Globular whey proteins contain acidic/basic and hydrophilic/hydrophobic AAs along their
polypeptide chains, well balanced throughout α-helix motifs [35]. With increased magni‐
tude of dairy industry, enormous quantity of whey is produced across the globe. A substan‐
tial portion of it is wasted or underutilised as animal feed, in turn increasing the cost of its
disposal. Use of whey as a source of BAP provides economic health potential for global
population [37, 38]. Under controlled conditions, hydrolysis of whey releases peptides that
could be a part of preventive or therapeutic applications [39]. Recent literature reports some
biologically important whey peptides: α- and β-lactorphin, lactoferricin B, glycomacropep‐
tide (GMP) to name a few. Commercial formulations with whey as an ingredient are also
available, making it a value-added product [40].
3. Production and purification of milk BAPs
Selection of appropriate food protein followed by its enzymatic hydrolysis is the general
process used for BAP production. BAPs can be released by in vivo or in vitro hydrolysis of the
parent proteins. They can be produced in vitro by (1) enzymatic hydrolysis with digestive
enzymes, (2) fermentation of milk with proteolytic starter cultures and (3) proteolysis by
enzymes derived from animals, plants or microorganisms [14]. Once the AA sequence is
known, it is also possible to synthesise BAPs through the chemical methods, enzymatic
synthesis and/or by recombinant DNA technology [15].
3.1. Protein hydrolysis under simulated gastrointestinal tract conditions
In vivo digestion of protein, although possible, is rarely used for the production of BAPs as it
requires removal of intestinal contents from animals after feeding protein diet. However, it
can be simulated. The protein of interest is first treated with pepsin for a few hours to stimulate
digestion, followed by treatment with pancreatin or with a combination of trypsin and
chymotrypsin mimicking digestion in stomach at specific pH. This method also enables
estimation of BAPs released from food proteins though the stimulation of intestinal proteas‐
es after food intake is not taken into consideration [12]. BAPs produced via in vitro stimula‐
tion of gastric enzymes from milk are mainly ACE inhibitory peptides. Digestive enzymes in
combinations with other proteases from bacterial/fungal sources are also used in the genera‐
tion of BAPs from various food proteins [22].
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3.2. Fermentation with proteolytic starter cultures
The presence of lactic acid bacillus (LAB) in milk fermentation can be either as spontaneous
or as inoculated starter cultures. Although under spontaneous fermentations the growth of
LAB cannot be predicted or controlled, this procedure has been practiced and carried out
traditionally for years [41]. The fermentation process by lactic acid bacteria starter cultures,
used in the dairy industry, involves the hydrolysis of milk proteins (particularly casein) into
peptides and AAs which are used as nitrogen sources necessary for their growth. Several lactic
acid bacteria are widely used and their role can be divided into starter and non-starter cultures.
The proteolytic system of lactic acid bacteria consists of a cell wall-bound protease and other
intracellular proteases [42]. Different starter cultures and fermentation conditions affect the
composition and nature of released BAPs. Studies have exhibited that LAB proteases espe‐
cially from Lactococcus sp. and Lactobacillus sp. could hydrolyse ≥40% of peptide bonds of α1
and β caseins resulting in the release of various oligopeptides that are further hydrolysed by
complex peptidases [43]. Pure cultures as well as mixed cultures are used for fermentation.
Apart from lactic acid bacteria, yeast and other microflora may also be present in a few
commercial starter cultures. Peptide profiling of bovine kefir, which is a fermented milk
beverage, revealed 236 unique peptides that were released from caseins during its produc‐
tion by kefir grains [44]. BAPs with physiological benefits, such as ACE inhibition, immuno‐
modulation, anti-oxidative, antimicrobial, etc., have been identified from microbial fermented
products [45–47]. An endopeptidase from Lactobacillus helveticus improved the production of
casein-derived ACE inhibitory peptides, VPP (Val-Pro-Pro) and IPP(Ile-Pro-Pro) via carboxy
terminal processing mechanism [46]. Even with insufficient evidence to establish the cause–
effect relationship between the maintenance of blood pressure (BP) and the consumption of
fermentation-derived peptides, food products fortified with such BAPs could prove valua‐
ble as nutritional therapeutics at least in certain sub-population [42].
3.3. Enzymatic hydrolysis by proteases
Plant, animal and microbial proteases have been used for the production of BAPs from the
protein source. Enzymatic hydrolysis is more suitable for the production of BAPs, especially
in food and pharmaceutical industries, due to the lack of residual organic solvents or toxic
chemicals in the end product. Further hydrolysis takes place under mild controlled condi‐
tions and yield-predictable end product. The widely used enzymes of animal and plant origin
include pepsin, trypsin, chymotrypsin, bromelain, papain or ficin. One of the best and cheap
sources of animal origin proteinases is pancreases, by-products of the meat industry. Recently,
proteases from plant sources are gaining attention. ACE-inhibitory peptides and anti-ulcera‐
tive peptides were studied from peptides synthesised from whey protein hydrolysis by Cynara
cardunculus [48, 49]. Proteases from extracts of celery, fennel, parsley and ficin latex have shown
potential in releasing peptides from skim and whole milk with ACE inhibitory and antioxi‐
dant properties [50, 51]. However, these preliminary observations need further validation
through clinical studies involving human volunteers to confirm such promising in vitro/animal
study results [49]. Microbial proteases widely used are those obtainable from the Bacillus sp.,
Bifidobacterium, proteases from the LAB and few fungi [14, 17]. Furthermore, LAB and their
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products are considered safe (generally recognized as safe, GRAS). Microorganisms are a
relatively cheap source of proteases. Microbial proteases, especially from bacteria, provide few
advantages over proteases from other sources. A recent study showed that Bifidobacterium
bifidum MF 20/5, Arsukibacterium ikkense, L. helveticus, Bacilus thermoproteolyticus, etc., could
release peptides from milk and milk products that were potent ACE inhibitors, antimicrobi‐
al and antioxidant agents [52–55].
3.4. Chemical synthesis and recombinant DNA technology
Enzymatic production of peptides generally does not produce adequate quantities and is not
always economical. Chemical and recombinant technologies are used in such conditions to
produce peptides in large quantities. However, they require specialised equipment, skilled
labours and incur high cost. Further these techniques can be employed only when the peptide
sequence is known. The size of peptide determines the kind of technology to be used. Chemical
synthesis is preferred for producing medium and small peptides (5–80 AAs) and recombi‐
nant technology for larger peptides and proteins [56]. Numerous such peptides have been
approved to be used as drugs in the past decade. This application greatly depends on chemical
modifications of peptides to improve membrane permeability, receptor affinity and stability
along with decrease in hepato-renal clearance of the peptide. It is also proven that bioavaila‐
bility of peptides improves with chemical modification, such as bond replacement and
conformational modifications including peptide cyclisation. Chemical synthesis has proved
that large-scale peptide synthesis at reasonable cost can be achievable through solid phase [57].
Easy peptide separation from other products and impurities remain its major advantage.
However, requirement of side-chain protection, racemisation, decrease in yield during
removal of protective chains and toxic nature of solvents used are a few drawbacks associat‐
ed with this method. Chemical synthesis is still considered as one of the best suited proce‐
dures to synthesise medium-sized peptides of therapeutic significance [16].
Recombinant DNA technology involves gene expression in microorganisms using modern
techniques of cloning to synthesise one or more peptides concurrently. This method requires
high cost involving research; however once established it will lead to their economic yield. The
Escherichia coli based bacterial expression system is widely preferred. Human and bovine β-
casomorphins were produced through this technique [15]. Particularly, this technology finds
superiority in synthesis of large peptides and proteins [16]. Additionally, it comparatively
offers effective alternative for bulk production of peptides [58].
3.5. Purification and characterisation
Purification of peptides after its production from any of the above-mentioned process is
prerequisite for its industrial use. Peptides with more than 95% purity is required for NMR
studies, enzyme studies, monoclonal antibody production, in treatment of disease, clinical
research and structure–function relationship studies. Immunological studies and PAGE
analysis require purity of >70–80% [58]. Ultra-filtration is performed using series of mem‐
brane filters with different molecular weight cut-off resulting in minimising non-peptide
concentration in the hydrolysate. Purification procedure often used is RP-HPLC. This enables
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rapid purification and detection of peptides in a mixture. Ion exchange, affinity, size-exclu‐
sion chromatography and capillary electrophoresis are also being preferred [12]. Peptide
characteristics are evaluated through mass spectrometry [58].
4. Absorption of BAPs
BAPs produced after their release from parent proteins by GI enzymes at times exert their
activity locally or after absorption at the peripheral organs [14]. Some peptides may undergo
further hydrolysis by peptidases in the course of transport of brush border and cytoplasm.
Intestinal absorption plays an important role in the effectiveness of their biological functions.
Even with little unambiguous in vivo evidence, the absorption of BAPs is suggested to be
possibly operating through any of the following pathways: carrier-mediated transporter
system, passive diffusion and transcytosis, paracellular pathways via tight junctions and
endocytosis [21].
4.1. Carrier-mediated transport system
Carrier-mediated transport system actively transports bi- and tripeptides. Cytoplasmic
peptidases hydrolyse peptides to AAs in the intestinal epithelial cells; however, some peptides
resist this hydrolysis and are transported across the membrane [59]. PepT1 (transmembrane
protein) is an intestinal proton-dependent peptide transporter with a wide range of sub‐
strate specificity for more than 400–800 di- and tripeptides. L-AA-containing peptides are
preferred over D-AA/D-stereoisomers for transporting across membranes [60]. It is a bidirec‐
tional transporter where membrane potential and proton gradient decide the rate and direction
of absorption. About 70–80% of peptides are absorbed through PepT1 transport system due
to its high transporting capacity and intestinal expression [61].
4.2. Passive diffusion and transcytosis
Maternal colostrum-derived γ-globulin permeability associated with passive immunisation
by mammalian neonatal small intestine has long been established. Lipid-soluble peptides
easily enter enterocytes and are hydrolysed by the action of cytosolic peptidases releasing AAs
for intercellular metabolism. Some AAs from enterocytes are moved into portal circulation
through transporters on basolateral membrane [62]. Role of this system in absorption is
considered small, as peptides are most likely to be hydrolysed by cytoplasmic peptidases [63].
Large polar proteins (>600 Da) are hydrolysed before they enter into enterocytes. Vesicles are
formed by invagination of apical membranes that capture the large peptides. These vesicles
fuse with lysosomes to form phagolysomes where enzymatic digestion of the macromole‐
cule occurs. Proteins that resist this hydrolysis could be drawn into enterocytes by means of
receptor-mediated, absorptive or fluid-phase transcytosis to be secreted into basolateral
membrane. Di- and tripeptides are generally hydrolysed by cytosolic peptidases; however,
those that resist are hydrolysed by vascular endothelial tissue/plasma peptidases [63–65].
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4.3. Paracellular pathway through tight junctions
Paracellular pathway is considered important in BAP absorption in intact form. Tight junctions
are formed by adhesive membrane proteins (claudins, occludin, tricellulin and junctional
adhesion molecule A) between intestinal epithelial cells creating small pores to enable passive
diffusion of peptides. Diffusion through tight junctions depends on permeability and elasticity
of these junctions that are controlled by these proteins [65, 66]. Tight junctions generally allow
diffusion of cations and inert small molecules (<600 Da) and also larger oligopeptides [67].
4.4. Endocytosis
Intestinal epithelium of adult mammals could absorb proteins in small quantities by endocy‐
tosis even though such absorption is much smaller (<0.1%) in comparison with other absorp‐
tion system; however, they are biologically significant. Larger peptides are generally
internalised by endocytosis [fluid phase and/or absorptive (receptor)]. Fluid phase (pinocyto‐
sis) is non-specific endocytosis that begins with plasma membrane “pinching off” to vesicle
that contains dissolved peptides in extracellular (EC) fluid. Vesicle or pinosome drifts inwardly
to perinuclear region to bind with lysosome. Peptides are hydrolysed during this and vesicle
is recycled back to plasma membrane. In absorptive or receptor endocytosis, the membrane
binding site is specific for the peptide to be transported. Receptor–ligand binding results in
clustering of this complex into clathrin-coated regions of plasma membrane followed by
endocytosis. These complexes are transported to endosomes where low pH of the endosome
disassociates receptor–ligand complex and receptor is either recycled to plasma membrane or
may be degraded [67, 68].
5. Bioactivities of BAPs from milk
Naturally occurring bioactive molecules are preferred in comparison with chemosynthetic
components for functional food preparation. Protein-derived BAPs are presently gaining
attention due to their safe and economic benefits [69]. Food technologists and scientists have
been concentrating in understanding relationship between casein- and whey-derived BAPs
with their bioactivities. Deciphering their AA sequences along with an understanding on their
bioavailability and stability in vivo have helped in the development of health-promoting milk
protein [70]. Figures 1 and 2 illustrate various bioactivities of milk-derived peptides. However,
relationships between their structural properties and functional activities have not been
completely elucidated. Many BAPs from milk proteins are relatively small (e.g., 2–9 AAs),
possessing hydrophobic AA residues in addition to proline, lysine or arginine groups. Several
in silico approaches including quantitative structure activity relationship (QSAR) as an
application of chemometric and bioinformatics methods have been used in an attempt to
predict the activity of these peptides. Structure–function relationship elucidating studies
highlighted the significant contribution by specific AA residues, such as tyrosine (Y), leucine
(L), proline (P) and tryptophan (W), present in BAPs for diverse physiological activities [71].
Recent studies have shown that many tryptophan(W)-containing peptides originate from milk
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proteins, which have been shown in vitro to display a wide range of bioactivities such as ACE
inhibition along with antioxidant, antidiabetic and satiating-related properties [71].
Figure 1. Physiological role of milk bioactive peptides [72, 26].
Figure 2. Representative BAPs from milk proteins and their prominent bioactivities [40, 73, 74]. *AA represented by
one letter code.
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5.1. Functionalities of casein and whey peptides
5.1.1. Mineral binding property
Normal bone development in humans requires adequate calcium supply. Low ingestion of
calcium levels are prevalent among infants (mostly pre-term), young and post-menopausal
women, elderly who have low calcium absorption and those in treatment or prevention of
osteoporosis and children with rickets [75]. Enhancement of Vitamin D-independent bone
calcification was the suggested role of casein-derived phosphorylated peptides in rachitic
infants [14]. Specific caseinophosphopeptides (CPPs) that are phosphorylated regions released
form α- and β-caseins can form soluble organophosphate salts functioning as mineral carriers,
especially for calcium. CPPs were the first BAPs to be mentioned by Mellander [28] in 1950.
CPPs have been shown to possess mineral binding properties thereby improving bioavaila‐
bility of metal ions [76]. CPP-ACP (amorphous calcium phosphate) exhibited anti-plaque,
remineralisation and demineralisation prevention of teeth [77]. Increased bioavailability of
iron in the presence of CPP has also been reported [78]. Whey peptides also exhibited mineral-
binding properties [79]. Tryptic hydrolysates of whey proteins inhibited calcium phosphate
formation thereby favouring calcium absorption. [80]. Significant elevation in mice calcium
absorption in the presence of tryptic hydrolysate of whey (Ser-Thr-Glu-Tyr-Gly) suggested
their possible utility as functional food or dietary supplement to prevent calcium deficiency
[81].
5.1.2. Antioxidant activity
Aerobic metabolism inherently releases free radicals which are scavenged by antioxidants in
the biological system that protects against the damage caused by reactive oxygen species. Free-
radical-mediated reactions play a major role in cellular damage and aging via lipid oxida‐
tion and production of secondary lipid products contributing to major degenerative diseases,
such as CVD, diabetes and even in neurological disorders [82]. A number of milk BAPs have
been shown to possess antioxidant property. This ability of peptides to bind/interact with
radical species and/or inhibit oxidation could be a boon to boost human health [83]. Casein
peptide, derived through pepsin hydrolysis, bearing the sequence Tyr-Phe-Tyr-Pro-Glu-Leu
(YFYPEL) was found to show superoxide anion scavenging activity [84]. Further they
identified that the preferred sequences were EL>YFYPEL>FYPEL>YPEL>PEL, suggesting that
Glu-Leu in the sequence is important for this activity. Casein-derived peptides exhibited
antioxidant property via inhibition of lipid peroxidation. It was further observed that
proteolysis or dephosphorylation of casein did not impair its antioxidative potential [85].
Peptide with SerP-SerP-SerP-Glu-Glu domain has proven to possess free radical scavenging,
hydroxyl and metal chelating properties [19, 86]. A recent study on peptides derived from
sodium caseinate by proteases (papain, trypsin and pancreatin) demonstrated the contribu‐
tion of proteolytic conditions on the extent of antioxidant activity [87]. Antioxidative poten‐
tial of whey protein hydrolysates (WPHs) was associated with both low and high molecular
mass fractions [88, 89]. α-Lactalbumin (α-LA) hydrolysed by thermolysin-yielded peptides
with antioxidative properties. Peptides with Trp or Tyr at their extremities were found to
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possess higher antioxidative activity in comparison with gallic acid and Trolox [90]. Trp-Tyr-
Ser-Leu purified from whey protein displayed high radical scavenging and superoxide radical
scavenging activities among peptides obtained through other enzymes [91]. Many peptides
from whey have been shown to be multifunctional and possess antioxidant property along
with ACE inhibition and antimicrobial properties [92, 93]. IIAEK and IPAVFK peptides,
derived from tryptic hydrolysate of β-lactoglobulin (β-LG), possessed potent ACE inhibitor
potential while VAGTWY was found to be an effective antioxidant having 1.7-fold higher
activity in comparison with commercial antioxidant [94]. Hydrolysates derived from sheep
cheese whey through hydrolysis by protease from Bacillus species P7 were effective as
antioxidant and antihypertensive agents. They exhibited 3.2-fold increases in radical scaveng‐
ing activity and could potentially be engaged in retarding oxidation in food products or as a
nutraceutical [95].
Lipid peroxidation leads to spoilage, reduced shelf life along with release of free radicals that
possibly decrease the nutritional value of food. Independent or combined antioxidant or
antimicrobial roles by whey BAPs have extended their utility as natural food preservation
agents. Ability of lactoferrin (Lf) to retard growth of microbes or limit lipid oxidation finds its
application in food preservation as it acts as antimicrobial and physical barrier between food
and microbes. It can also be used as spray or directly applied to beef carcasses improving its
shelf life [96]. Peptide sequence Trp-Tyr-Ser-Leu-Ala-Met-Ala-Ala-Ser-Asp-Ile from α-LA
and β-LG hydrolysed by commercial proteases was found to possess radical scavenging
activity higher than butylated hydroxyl anisole indicating its utility as antioxidant in food
industry [97]. Alcalase-treated whey protein isolate (WPI) hydrolysates proved to possess
antioxidant property by acting as metal ion chelator, radical stabiliser and hydrogen donor
thereby inhibiting lipid oxidation ascertaining their potential to replace synthetic antioxi‐
dants [98]. Radical scavenging activity of fragments LQKW and LDTDYKK of β-LG-en‐
riched WPC were identified [99]. Antioxidant peptides and their application have been
reviewed by Power et al. [18]. Critical contribution of thermal processing contributing to
maintenance of milk protein bioactivity was delineated. Lf and β2 transforming growth factor
were significantly high in low-heat-treated WPC mainly from acid whey that could induce
immune response via proliferation and cytokine responses of intestinal epithelial cells. These
findings could be vital in maintaining optimal bioactivity infant’s formula thereby influenc‐
ing maturation and immune modulation of developing intestine [100].
5.1.3. Angiotensin-converting enzyme inhibitors
CVD is the leading cause of mortality and morbidity globally. BAPs from milk have gained
prominence in protection against CVD owing primarily to their antihypertensive effects along
with hypocholesterolaemic, anti-inflammatory and anti-oxidant potentials [101]. Multifunc‐
tional ACE regulates blood pressure via catalytic conversion of angiotensin 1 to angiotensin 2
which is a potent vasoconstrictor. ACE inhibition is known to be the major strategy in BP
treatment using pharmacological drugs. Due to their side effects, there is continuous search
for safe and possibly natural inhibitors [102]. Extensive research has been focussed on ACE
inhibitory biopeptides. Casokinins that are casein-derived peptides, found in α1-, β- and κ-
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caseins, are very effective in inhibiting ACE [72]. Casein peptide, VPP, is a potential inhibi‐
tor of ACE. Research suggests that monocyte adhesion to inflamed endothelia is well
moderated by VPP that may prove vital in the prevention of atherosclerosis [103]. Pepsin
hydrolysed bovine casein (HBC) with molecular mass <3000 were studied for their antihyper‐
tensive property. HBC exhibited nearly 10 times decrease in DBP substantiating its potential
as ACE inhibitor and an antihypertensive agent. Pepsin hydrolysate of casein has been
commercialised and patented as potential hypotensive agents containing α1 peptides [99, 104].
Structure–activity studies have shown that three residues in the C-terminal region of BAPs
seem to interact with active centre of ACE. This interaction may enhance the ACE inhibitory
activity if hydrophobic/aromatic AAs (Trp, Tyr and Phe) or imino acid Pro are situated in this
location. Additionally, Arg and Lys residue’s positive charge may increase the inhibition [105].
Further C-terminal region’s importance in ACE inhibition was delineated through QSAR
model [106, 107]. A recent study on α-casein-derived peptides identified a potent ACE inhibitor
using endoproteinase from Aspergillus niger [108]. Enzymatic hydrolysis of β-LG obtained from
chemical hydrolysis of ovine and caprine whey exhibited consistently high ACE activity. It
was postulated that end product of thermolysin hydrolysates, LQK from LQKW and LL from
LLF, possibly possessed ACE inhibitory action [109, 110]. Stage 1 hypertensive young adults
treated with dietary intake of WPC beverage daily for 6 weeks resulted in a significant decline
in diastolic and systolic blood pressure [111]. Hydrolysates of camel milk, colostrum and
colostral whey proteins by pepsin and pancreatin to mimic intestinal digestion presented
increased ACE inhibition along with multifunctional effects like radical scavenging and
antimicrobial effect. Biopeptides α-LA and immunoglobulin (IgG) exhibited multifunctional
activity including ACE inhibition [92]. Recently, optimisation studies to produce whey
hydrolysate from WPC containing 70% protein with commercial enzyme through response
surface methodology demonstrated up to ~65% inhibition of ACE and 50% antioxidant
property [93].
5.1.4. Opioid activity
Opioid peptides are short sequence AAs required by the brain for important functions and
these mimic the effect of opiates in the brain. Opioid peptides are peptides that exert affinity
towards opiate receptors. Some of the functions of these peptides are to increase analgesic
action, moderate social behaviour, stimulate endocrine secretions, increase GI transient time
and thereby inhibiting intestinal peristalsis, motility, etc. [112]. Activity of opioid agonist
peptides is inhibited by the opioid antagonist naloxone both in vitro and in vivo. All opioid
receptor ligands are proved to possess some characteristic features, such as N-terminal Tyr
residue, another Phe, Tyr or another aromatic AA at the third or fourth position from the N-
terminal end. These features ensure appropriate fit between the peptide and receptor for the
specific target activity [113]. One of the earliest discovered BAPs from milk was casein opioid
peptide, β-casomorphins. Water buffalo, sheep and human milk also contain analogues of β-
casomorphins. Exorphins derived from α-casein of milk corresponding to bovine α1-casein
and casoxins from κ-casein mimic as opioid antagonists [114]. Recent research on casein-
derived β-casomorphins-7 has shown to have positive influence on neurogenesis through
redox-based epigenetic effects [115]. Enzymatic hydrolysis of whey by GI enzymes individu‐
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ally or in combination was used in vitro to release an agonist peptide, serorphin, from bovine
serum albumin (BSA). It also led to the production of antagonist peptides, lactoferroxin A, B
and C from Lf, α- lactorphin from α- LA and β-lactorphin from β-LG [116]. α-Lactorphin was
shown to upregulate mucin gene (MUC5AC) expression and secretion in human colonic
goblet-like cells [117]. Trypsin hydrolysates of β-LG and β-lactorphin exhibit similar results
possibly operating via opioid pathway. Results confirm that mucin secretion could be induced
via opioid receptor and whey peptides as promising gastrointestinal protective agents [118].
5.1.5. Antithrombotic activity
Rennin hydrolysis of κ-casein during milk clotting releases caseinomacropeptide (CMP) that
contain peptide sequences aiding blood clotting by inhibiting platelet aggregation and binding
of γ chain of fibrinogen to fibrinogen receptors [119]. The sequences LSFMAIPPK,
MAIPPKKNQDDK, MAIPPKK and NQDK in primary structure of κ-caseins were found to be
involved in antithrombotic activity [119, 120]. κ-Caseinoglycopeptide from sheep casein
exhibited antithrombotic property [121]. Undecapeptide (106–116) of bovine κ-casein exhib‐
its structural similarities to dodecapeptide of human fibrinogen γ chain at C-terminal. Ile108,
Lys112 and Asp115 residues of undecapeptide are positionally homologous with r-chain of
human fibrinogen for platelet receptors thereby inhibiting clot formation [122].
5.1.6. Antimicrobial activity
Conventional antibiotics use is increasingly turning deterrent due to antibiotic resistance by
microorganisms resulting in treatment impediments and augmented healthcare expenses.
Antimicrobial peptides (AMPs) resulting from milk have the advantage due to their precise
infected cell targeting, broad spectrum nature, safe and economical source with vast industri‐
al potential [17, 20, 71]. Antimicrobial properties of milk was first identified in 1930 when
lactenin was identified to possess antibacterial property against scarlet fever Streptococcus
[123]. Research has shown that milk proteins contain several motifs that can be released by
proteolytic enzymes to enhance the antimicrobial potential of these proteins [124]. Disease
prevention/control through BAPs primarily involves microbial interaction as AMPs or
immunomodulation [125]. α1-Casein-derived peptides, casecidins, were the first purified
antibacterial peptides from casein and were effective against a wide range of Gram-positive
bacteria including Staphylococci. Isracidin, N-terminal peptide of α1-casein was found to be
effective against Lactobacilli and Gram-positive bacteria in vitro and yielded a strong protec‐
tion against Staphylococcus aureus, Listeria monocytogenes and Streptococcus pyogenes in vivo.
Isracidin is comparable in its antibiotic action to standard commercial antibiotics in protect‐
ing cows and sheep against mastitis [126]. Caseicin A, B and C from α1-casein share common
characteristics with isracidin in their AMPs. Caseicin A and B were effective against E. coli and
Enterobacter sakazakii while caseicin C only showed minor activity against Listeria innocua [127].
Peptides obtained from bovine α1-casein by Lactobacillus acidophilus DPC6026 fermentation
have been active against infectious pathogenic strains in neonate, E. sakazakii and E. coli
suggesting the possible bioprotective applications of these AMPs in infant milk formula [128].
Digestion of casein with pepsin yielded two AMPs, Cp1 from α1-casein and Cp2 from α2-casein.
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Cp1 was effective against both Gram-positive and negative bacteria whereas Cp2 exhibited
inhibition generally more towards Gram-positive bacteria [129]. Casocidin-I (165–203)
characterised and isolated from bovine α2-casein was effective against E. coli and S. cornosu in
infants. Human milk does not contain α2-casein and hence it was proposed that human
intestinal flora was influenced by casocidin-I ingestion [29]. Chymosin digestion of sodium
caseinate resulted in the release of five antibacterial peptides (Cr1, Cr3, Cr4, Cr5 and Cr7) that
were found potent against Gram-positive bacteria [130]. Peptide from human β-casein (184–
210) showed broad spectrum antibiotic activity against Gram-positive and negative bacteria.
Fragment from rabbit β-casein (64–77) exhibited potent action against Gram-positive bacte‐
ria [105]. Ser(P)149, a mono phosphorylated sequence of κ-casein (138–158), also displays
antibacterial effects against Porphyromonas gingivalis, E. coli and S. Mutans [74]. κ-Casein-
derived AMPs, kappacin, is a non-glycosylated and phosphorylated form of CMP. These
peptides limit GI tract infections in neonates possibly by transmembrane cation gradient
collapse and by elevating bacterial sensitivity to gastric acids [105]. CMP by itself is a power‐
ful health booster. It is effective against cholera toxins as well as influenza virus. Prevention
of bacteria adhesion to oral cavity by CMP controls dental plaque consequently promoting
teeth remineralisation. CMP has also been patented in hygiene products for dental caries
prevention [131]. κ-Casecidin, trypsin digest of κ-casein, exhibited both antimicrobial potential
and mammalian cell cytotoxicity including cell lines of human leukaemia probably through
apoptosis [127]. Whey protein Lf has been considered as a good source of AMPs. A cationic
peptide, from Lf N-terminal region, lactoferricin 27, binds to microbial membrane and
increases its permeability causing cell death. Potential to bind iron, a pathogenic virulence
factor of many bacteria, and depriving it from cell vicinity has been another mechanism by
some whey-derived AMPs especially on E. coli and L. monocytogenes [132]. Three α-LA
hydrolysates by trypsin and chymotrypsin was found potent against many Gram-positive
bacteria, especially Bacillus subtilis. Four peptide fragments from trypsin digests of β-LG
exerted bactericidal property only against B. subtilis [132]. Targeted modifications after partial
hydrolysis by pancreatic enzymes improved antimicrobial property by β-LG towards Gram-
negative bacteria [132]. Whey proteins and their chemically modified analogues were effective
against Helicobacter pylori infections and exhibited antiviral activity towards human herpes
simplex virus type 1 (HSV-1) during and after infection [35]. Fungal stasis and antifungal role
of Lf and its synthetic peptides are well established against Candida albicans, Candida glabrata
and other Candida species [39]. Whey from goat milk on hydrolysis with gastric and duode‐
nal juices exhibited antimicrobial properties. Nature of protein substrate and proteases affect
AMP generation and their efficacy. Camel milk whey protein exhibited higher inhibition of E.
coli in comparison with that of bovine. Camel whey hydrolysates by trypsin, thermolysin and
chymotrypsin showed increased antimicrobial activity [133]. Peptic and pancreatic hydroly‐
sates of camel colostrum proteins were inhibitory to growth of E. coli and L. innocua signify‐
ing their natural antimicrobial potential [92].
The biggest challenge faced by researchers in food-borne pathogen control is tolerance to high
salt and low pH by a wide range of microorganisms (bacteria, fungi and viruses). Novel
antimicrobial agents from natural sources are therefore the need of the hour to overcome this
challenge [134]. Recent past has witnessed a rise in interest towards the use of BAPs as bio-
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preservative for food or as functional food that is more prophylactic, nutritious and healthy
[128]. This extended application of AMPs is advantageous over chemical food preservatives
as they introduce fewer antagonistic effect, retain the organoleptic flavours of food along with
their nutritional benefits and require decreased heat treatment for minimal processing [74,
105]. Milk-derived AMPs find immense potential in therapeutic healthcare and food preser‐
vation.
5.1.7. Immunomodulatory property
Body’s immune system protects it from pathogens through its specialised cells, antibodies and
lymphatic system. Dietary composition and their intake play a vital role in body’s immune
system. Immunomodulation includes stimulation or suppression of immune functions in the
human body. BAPs from innumerable sources have revealed their immunomodulatory role
in humans. They are identified to boost the immunological activity by regulating antibody
production, cytokine regulation and reactive oxygen species induced immune functions [127].
Neonates’ resistance to microbial infections is through physical transmission of passive
immunity through breast feeding via a number of multifunctional factors including casein,
which on digestion in GI tract releases peptides with immunomodulatory functions [72]. β-
Casomorphin-11, a hexapeptide corresponding to Val-Glu-Pro-Ile-Pro-Tyr possessing
immunostimulatory effect, was isolated from tryptic digest of β-casein of human milk. Several
other hydrolysates from β-casein (191–193) and α1-casein (194–199) including β-casomor‐
phin-11 exert protection against Klesieblla pneumoniae in mice in vivo and activate phagocytic
action in human and murine macrophages in vitro [30]. β-Casokinin-10, obtained via pepsin–
chymosin hydrolysis of bovine casein, stimulated proliferation of peripheral blood lympho‐
cytes in rats. Stimulatory effect on proliferation of human peripheral blood lymphocytes was
presented by synthetic peptide sequence analogue from bovine κ-casein (Tyr-Gly) [135].
Chymosin-mediated bovine casein hydrolysis released fragments (1–23 and 193–209 of α1-
and β-caseins, respectively) with immunomodulatory capacities. CPP III, a commercially
available CMP containing mainly α2-casein (1–32) and β-casein (1–28), increases immunoglo‐
bulin production in spleen cell cultures of mouse. Further, it induces proliferation by lipopo‐
lysaccharide, concavalin A (Con A) and phytohaemagglutinin. O-Phospho-l-serine residue of
CPP III was found to be responsible for this immunostimulating activity and therefore study
suggested relative stability of this peptide even with GI tract proteinase action. These
observations were considered vital for developing infants’ formula with optimised immuno‐
modulatory activities [72]. Enhanced mucosal immunity was observed in mice with oral
administration of CMP [15]. Immunotherapy against HIV virus displayed positive results in
decreasing the tendency to progress to AIDS (in patients with pre-AIDS) probably by inhibiting
the infection development [136]. Eight casein hydrolysates’ (titled a–h) bioactivities were
assessed for their antioxidant and immunomodulatory response. Hydrolysates (d–h) exhibit‐
ed increased Con A-stimulated IL-2 production; however, IL-10 was least stimulated in Jurkat
cells in culture [47]. Further studies revealed cross-linking of sodium caseinate with transglu‐
taminase before hydrolysis by Prolyve 1000 (microbial proteolytic preparation) had a positive
impact on anti-inflammatory functions in Jurkat cells [137]. Peptides with immunosuppres‐
sive property are utilised during medical conditions like grafting and transplantations and
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also during autoimmune disorders whereas stimulative immune peptides are required for
overall immune strength. Immunopeptides released after digestion in adult human are not
significant to stimulate immune response for therapeutic purposes [138]. Whey peptides have
exhibited its positive impact on immune system through various studies both in vivo and in
vitro [15]. GMP and its peptic hydrolysates were found to stimulate proliferation and phago‐
cytic activity of human macrophage-like cells U 937 [139]. Lymphocyte activation, antibody
production, non-immune responses like NK cell and macrophage functions are all reviewed
extensively by Gauthier et al. [138]. Cow and goat whey protein samples revealed in vitro a
dose-dependent inhibition of T-lymphocyte proliferation indicating the possible role of whey
peptides probably hindering some important proliferation activating signals [140]. Synthetic
peptides hydrolysed by trypsin or chymotrypsin on theoretical basis from α-LA (fragments
10–16 and 104–108) and β-LG (fragments 1–8, 15–20, 55–60, 78–83, 84–91, 92–105, 139–148, 142–
148 and 102–105) were evaluated for their immunomodulatory functions. Different extent of
proliferation stimulation was observed by fragments 15–20, 55–60, 84–91, 92–105, 139–148
and 142–148 from β-LG and α-LA 10–16, while inhibition and/or stimulation on cytokine
secretion was also observed by fragments 15–20, 55–60 and 139–148. Cytotoxic effect was
predominant in β-LG 1–8, 102–105 and α-LA 104–108. Studies show whey-derived peptides
to have prospective to modulate specific immune response [141]. Rat and mice models have
shown that dietary intake of whey adds positive influence in combating small bowels by
reducing ulcers and having high IgA in gut advocating their protective role in patients with
intestinal disorders and perioperative damage to small intestine [142, 143].
5.1.8. Anticancer property
In spite of promising results from anticancer studies on casein peptides, casein is not regard‐
ed as chemo preventive. β-Casein derivatives, β-casomorphin-7 and 5, along with their opioid
properties, have displayed arrest of cell cycle and anti-proliferative properties in colon and
breast cancer cells [144, 145]. CPPs inhibit intestinal tumour proliferation through activation
of calcium channels and stimulate apoptosis [146]. Calmodulin (CaM), a calcium activated
protein, plays a major role in physiological maintenance of the body functions, such as cell
proliferation and neurotransmission. CaM binding properties of food-derived peptides prove
vital in preventing many chronic diseases including Alzheimer’s and cancer [12]. Nitric oxide
synthases (NOSs), protein kinase II and phosphodiesterase I (PDE) are some of the major
enzymes that require CaM for their activation. Nitric oxide produced from arginine by CaM-
dependent NOS is involved in neurotransmission, immune response and other vital muscle
movements along with several other functions in the body. In excessive levels, it may lead to
degenerative nervous disorders, such as stroke, Parkinson’s, Alzheimer’s, etc. NOS exists in
three isoforms and depends on CaM for their activation. Inhibitors of CaM are effective against
these isoforms. One isoform is involved in tumour necrosis factor production by macrophag‐
es and hence CaM inhibitory substances during diseased conditions could provide therapeu‐
tic benefits [147]. Similarly, CaM-PDE catalyses the breakdown of cAMP to linear nucleotide
phosphate. Apoptotic cell death of normal and cancer cells is induced by cAMP in human
body. CaM-PDE in excess causes depletion of cAMP leading to physiological imbalance in cell
death. Inhibitors of CaM-PDE increases cAMP cellular levels that could offer therapeutic relief
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during cancer treatment. BAPs can exhibit effective CaM inhibition when they have hydro‐
phobic AA residues and positive charge at physiological pH to interact with CaM [148]. Pepsin
mediated hydrolysis of α-casein released such five peptides that were potential CaM-PDE
inhibitors [12]. Whey protein and its derivatives suppress tumour growth by elevating
glutathione levels and consequent free radical scavenging. The significant abundance of
cysteine, an essential AA required for glutathione synthesis, in β-LG may be contributing to
peptide’s tumour protective role [15]. Tumour preventive role by peptides could also be
through their modulatory effect on immunity and cell viability [149]. Tumour development
and progression of lung, colon and oesophagus was found to be inhibited in both rat and mouse
models after oral administration of bovine Lf. However, studies could not resolve its mode of
action [15]. Apoptosis-inducing property of α-LA was exhibited on tumour and immature cells
but not on mature cells. This property was attributed to its 3D protein folding that is unlike‐
ly of its native form [150, 151]. Case reports presented anti-tumour effect by whey proteins on
urogenital cancer when administered as dietary supplements. However, further clinical trials
were required to confirm its efficacy as therapeutics [152]. N-terminal peptides of Lf are
investigated for their anticancer activity. Fragments of bovine Lf 17–38 induced apoptosis in
HL-60 cell lines and fragments 17–41 exerted cytotoxicity in melanoma, colon carcinoma and
fibrosarcoma cell lines. Cytotoxicity of Lf was found to be located within FKCRRWQWRM
sequence. In vivo and in vitro cytotoxic effects on neuroblastoma cells and breast cancer cells
were exhibited by lactoferricin B and lactoferricin, respectively. Lf further displayed capaci‐
ty to inhibit angiogenesis required for tumour growth [74]. Human α-LA made lethal to
tumours (HAMLET) and bovine α-LA made lethal to tumours (BAMLET) are complexes of
calcium depleted or apoform of α-LA that exhibited anti-tumour activity in human studies.
Skin papillomas treated with HAMLET (skin application) for 3 weeks exhibited reduction in
lesion volume in relatively 75% of test group and further complete lesion resorption with 2-
year symptom-free period [153]. Apoptosis along with decreased size and surface atrophy of
tumours were observed in bladder cancer patients treated with HAMLET [154]. Daily
supplementation of bovine Lf for a year significantly arrested growth of colorectal polyps in
animals possibly through its iron chelating property [155]. Bovine Lf-treated colorectal cancer
patients undergoing chemotherapy showed relief from chemotherapy side effects (kidney and
liver toxicity, mucositis and anaemia) compared to the controls with no impact on normal cells;
however the results did not achieve statistical significance [156]. WPH exhibited low tumour
multiplicity in rats with chemically induced mammary tumours when fed as diet in compar‐
ison with casein hydrolysates, 20% casein and intact whey [157].
5.1.9. Miscellaneous properties
Various other health potentials of casein/whey peptides are also explored by researchers
worldwide. Type 2 diabetes, a globally prevalent metabolic disorder characterised by impaired
insulin secretion by pancreatic β cells is considered an epidemic in recent past. Its associa‐
tion with increased risk of chronic health issues including CVD and hypertension makes it a
public health burden resulting in elevated healthcare cost globally. This has led to research
towards finding an economic nutritional approach to improve postprandial glycaemia.
Dietary modifications alone in numerous million cases could prevent this disorder [158, 159].
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Epidemiological studies support positive correlation between intake of milk and dairy
products with its lesser incidence. The positive impact of milk on insulin resistance is majorly
attributed to its proteins and peptides that is validated through in vitro and in vivo studies [101].
Human studies on metabolic effects of milk proteins on glycaemia and insulinaemia exhibit‐
ed higher insulinotropic activity by whey in comparison with casein, other protein-rich food
and supplements possibly owing to faster rate of whey digestion [158]. The positive effect of
WPHs as an insulinogenic agent has also been evaluated. Whey proteins are considered as an
excellent source of insulin regulators due to its rich (40–50%) essential AA composition. These
AAs are primarily involved in inducing and modifying insulin secretion by β cells of pan‐
creas [160]. Experimental evidence suggested faster gastric emptying and subsequent
stimulation of incretin, an insulin secretagogue produced by small intestine (SI), in the
presence of hydrolysates of whey [71, 161]. Gastric emptying studies revealed influence of
different protein sources and their degree of hydrolysis on insulin response. WPHs lacking
carbohydrate stimulated rapid release of AAs, dipeptides (Val-Leu and Ile-Leu), along with a
significant increase in insulin secretion. Insulinotropic effect of whey hydrolysate is attribut‐
ed to increased postprandial concentration of AAs, such as Ile, Leu, Lys, Thr, Val, all of which
stimulate insulin secretion [162]. Animal studies on diabetes and β cells of pancreas were also
appraised [163]. Incretin [glucagon-like peptide (GLP 1) and glucose-dependent insulinotrop‐
ic polypeptide (GIP)] hormones contribute ~70% insulin release from pancreatic β cells.
Dipeptidyl peptidase (DPP IV), an abundant enzyme present in circulation and on cell surfaces,
acts on incretin decreasing their plasma levels. Inhibitors of DPP IV could improve half-life of
GLP-1 whose activity is preserved even during type 2 diabetes thereby stimulating its
insulinotropic effect. BAPs of whey from bovine, caprine and ovine are considered insulino‐
genic by acting as potential inhibitors of DPP IV [94]. Brandelli et al. have extensively reviewed
DPP IV inhibitors from whey proteins and their hydrolysates [40]. Yet another approach in
diabetes management involves inhibition of membrane bound α-glucosidase (carbohydrate
hydrolysing enzymes) from SI that catalyses release of monosaccharides from complex
carbohydrates. Inhibition of α- glucosidase delays carbohydrates degradation and thereby
decreasing the postprandial plasma glucose levels [164]. WPI, α-LA, β-LG and Lf hydroly‐
sates from peptic digestion were investigated for their DPP IV and α-glucosidase inhibition
potential. α-LA, β-LG and WPI hydrolysates were found to be potential inhibitors for both,
whereas Lf and serum albumin could inhibit DPP IV alone suggesting WPHs potential
antidiabetic property [165]. β-LG- and WPH-derived peptides by serine protease from
Cucurbita ficifolia were found to be potent natural inhibitors of α-glucosidase, DPP-IV and ACE.
The study supported antidiabetic nature of these peptides through inhibiting incretin and
carbohydrate digestion [166].
Muscles play a key role in whole protein body metabolism. They serve as reservoir of AAs,
which are required by vital organs and tissues for their protein synthesis when adequate AAs
are not available from gut absorption. It also provides hepatic glycogenic precursors. Any
impairment in muscle metabolism may thus check pathologic and chronic disease condi‐
tions. In order to maintain balance in rate of breakdown and synthesis of protein in vital organs,
postprandial absorption of proteins become vital especially for elders and sportsmen [167].
Protein homoeostasis by a suitable diet strategy is critical for growth, maintenance and/or limit
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loss of protein after stress. The quantity and quality of protein ingested could modulate protein
metabolism by its AA composition and digestibility [168]. Dietary protein from milk, meat,
etc., provides AAs that intensely stimulate protein synthesis in skeletal muscles [169]. Milk
proteins were investigated for their role in muscle mass maintenance and their possible role
as anti-aging factor. Whey proteins have proved to possess greater postprandial retention than
casein proteins. Improved anabolic properties of whey than that of casein was mainly
attributed to their faster digestion and absorption leading to increased availability of AAs to
stimulate protein synthesis [170]. Leucine has been recognized as important nutritional signal
to stimulate postprandial muscle protein deposit [171]. During aging, impairment of protein
synthesis in skeletal muscle postprandial results in a progressive decline in muscle mass
leading to sarcopenia [172]. Anabolic resistance towards muscle protein synthesis is consid‐
ered a major causative factor in sarcopenia [173]. Clinical trial has been registered for whey
proteins’ effective stimulation of protein accretion in muscle after ingestion of food in
comparison with casein [174]. Recent research on myofibrillar protein synthesis after inges‐
tion of whey in young men during rest and after exercise exhibited a 49–56% increase. The
study concluded that 20g dose of whey protein is adequate for maximum stimulation of
myofibrillar protein synthesis [175].
5.2. Dairy products
Starter cultures employed traditionally in dairy industry for milk fermentation release BAPs.
End products of dairy industry, such as fermented milk, cheese, etc., are found to possess
peptides that are biophysiologically active. Cheese is the oldest and widely used diary product.
It contains abundant casein-derived peptides formed during its production due to rennet-
based proteolysis. Subsequent ripening associated secondary proteolysis contributes to the
formation of diverse biologically active peptides whose function depends on the nature of
proteolytic enzyme used and the ripening stage of cheese [176]. Hydrolysates produced by
proteases differ according to their casein specificity. CPPs have been identified in Cheddar,
Comte and Herrgard cheese [21]. Various biological activities similar to casein and whey
peptides have been associated with varieties of cheese. Table 1 represents compilation of
antihypertensive peptides from selected commercially available cheese. VPP and IPP se‐
quence of several hard, semi-hard and soft cheese were also studied for their ACE inhibitory
properties [15, 177–182].
Antioxidant and antimicrobial activity were presented by cheddar and artisanal Coahlo cheese
peptides [182, 183]. Studies identified radical scavenging peptides from Burgos cheese made
by different proteases of animal (rennet), plant (C. cardunculus) and microbial (Mucor meihei)
origin. Cheese made by animal rennet could yield an antioxidant peptide from α1-casein [184].
Antihypertensive peptides from Calpis, a Japanese soft drink, were identified as VPP and IPP
from α1-casein and β-casein, respectively [136]. Peptides from fermented milk and yogurt from
bovine and sheep’s milk were evaluated for their antihypertensive and antioxidant activities
[97, 185]. A recent study on fermented camel milk (chal) and bovine milk using protease from
LAB exhibited significant antioxidant property in camel milk in comparison with its bovine
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counterpart [186]. Research stays on to find novel BAPs from various dairy products and to
disclose their probable values and health benefits.
Cheese type Source and peptide information
Cheddar α1-casein:1–6, 1–7, 1–9, 24–32, 102–110
β-casein: 47–52, 193–209
Fresco cheese α1-casein:1–15, 1–22, 14–23 and 24–34
β-casein:193–205, 193–207, 193–209
Spanish cheese Several fragments of α1 and β casein
Gouda cheese α1-casein: 1–9, β-casein: 60–68
Herrgard cheese β-casein: 29–105, 29–107, 1–105, 1–107, 29–93, 30–93
Italian cheese mozzarella, crescenza, Italico and Gorgonzola β-casein: 58–72
Parmigiano-Reggiano cheese β-casein:8–16, 58–77, α2-casein: 83–33
Table 1. Antihypertensive peptides from diverse commercial cheese [180–182].
6. Commercial products
Extensive evidence found in literature suggests potentiality of BAPs as therapeutic or dietary
supplements/functional foods. Commercial products enriched with BAPs are available in the
market with empirical knowledge from research [187]. Abundant potential is found in peptides
to be used as dietary supplements or as functional foods; however, they may not always be
included in regular intake as additional information regarding safety, cytotoxicity and
hypersensitivity as mandatory [47]. Food and oral hygiene products along with various
ingredients enriched with BAPs from milk proteins are available commercially. Table 2
represents selected products from milk-derived peptides with their claimed potential health
benefits. Various other food-derived BAPs are also available in market with substantial health
benefits associated with them. A few have been approved by FDA for therapeutic uses. One
of the major challenges for existing and future commercial peptide products is valid docu‐
mentation of the functional and health promoting properties associated with them [26, 70].
Protein  Peptide
sequence
Commercial product Food type Health claim Website/
manufacturer
Milk
proteins
Dipeptide and
tripeptides
PeptoPro® Ingredient Boosts muscle
protein synthesis
http://www.dsm.com/markets/
foodandbeverages/en_US/
products/nutraceuticals/
peptopro.html
DSM, Netherlands
α1-casein  YLGYLEQLLR Prodiet F200 Confectionary, Stress reliever www.ingredia.com/
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Protein  Peptide
sequence
Commercial product Food type Health claim Website/
manufacturer
Lactium drink Ingredia, France
α1, β-Casein IPP and VPP Calpis Sour milk Hypotensive www.calpis.net/
CalpisCo. Japan
β and
κ-casein
IPP and VPP Calpico/
Calpis AMEAL s
Fermented
milk
Hypotensive www.calpis.net/
Calpis Co., Japan
Casein-
derived
dodeca
peptide
FFVAPFPE
VFGK
C12 peptide Peptide
ingredient
Hypotensive www.dmv.nl/en/
DMV, Netherlands
Casein Casein
hydrolysate
Excellion Calcium
Caseinate A
Powder Nutraceutical www.dmv.nl/en/
DMV, Netherlands
Sodium
caseinate from
curd
Excellion OPTIMIX
100
Dried milk
protein
Nutraceutical www.dmv.nl/en/
DMV, Netherlands
Casein
hydrolysates
PROTARMOR™ 80 Ingredient Weight loss
Sports nutrition
http://www.armor-
proteines.com/en/products/
protarmor-80/
Armor Proteines, France
CPP Caploc CPP ingredient Mineral
absorption
www.arlafoodsingredients.com/
Arla Foods, Denmark
CPP CE90CPP ingredient Mineral
absorption
www.dmv.nl/en/
DMV, Netherland
CPP Kotsu calcium Soft drink Mineral
absorption
www.asahiinryo.co.jp/
Asahi Soft Drinks Co. Ltd,
Japan
CPP Tekkotsu Inryou Soft drink Mineral
absorption
www.suntory.com/softdrink/
Suntory, Japan
CPP-ACP Recaldent Tooth paste Remineralisation 
of enamel
http://www.recaldent.com/
p_welcome.asp
Cadbury enterprises
Whey
protein isolate
GMP (106–109) BiPRO WPI Ingredient and
infant formula
Antithrombic,
anticariogenic
Antimicrobial
www.daviscofoods.com/
specialty/bipro.html
Davisco foods, Minnesota
Whey
protein
hydrolysate
β-LG fragments Biozate 3 and 7 Ingredient Hypotensive www.daviscofoods.com/
specialty/biozate.html
Davisco foods, Minnesota
α-
Lactalbumin 
α-LA fragments Lacprodan®
ALPHA-10 and
Health food Improves sleep
and memory
www.arlafoodsingredients.com/
products/alpha-lactalbumin/
Milk Proteins - From Structure to Biological Properties and Health Aspects122
Protein  Peptide
sequence
Commercial product Food type Health claim Website/
manufacturer
Lacprodan®
ALPHA-20
health-foods/, Arla foods,
Denmark
Whey
protein 
WPC Hiprotal® Whey
Protein 35 and
Hiprotal® Whey
Protein 45
Ingredient for
infant nutrition
Muscle building  www.domo.nl/en/markets-
ingredients/list/infant-nutrition-
ingredients-list/
FrieslandCampina Domo,
Netherlands
Whey
peptide 
CMP Lacprodan® CGMP-10Infant food Cognitive and
neuronal
development
www.arlafoodsingredients.com/
products/
caseinoglycomacropeptide/
infant-nutrition/
Arla foods, Denmark
Whey
protein 
WPH Peptigen®
IF-3087/3090/3012/3080
Infant food Mineral binding  www.arlafoodsingredients.com/
products/whey-hydrolysates/
infant-nutrition/Arla foods,
Denmark
WPH Lacprodan®
DI-3071/3021
Lacprodan®
HYDRO.milk
Sports nutrition Vitamins and
minerals
uptake; oral
hygiene
improvement
www.arlafoodsingredients.com/
products/whey-hydrolysates/
sport-nutrition/
Arla foods, Denmark
Table 2. Commercial products from milk protein/peptides [70, 187].
7. Summary and future prospects
BAPs derived from milk proteins have been a subject of growing interest as health-support‐
ing foods due to their varied nutritional and biological properties. Several studies have shown
the role of BAPs as functional food and nutraceuticals. Still, the existence of milk-derived
peptides in the gastrointestinal tract has been demonstrated through only a handful of studies.
In addition, very little or no information about the stability, bioavailability and efficacy of these
BAPs generate a main breach in knowledge to allow an improved understanding on their role
in human health. There is still a need for the development of integrated research platforms
involving inter-disciplinary skills to bring more clarity on the role and mechanism of action
of milk-derived BAPs in humans. Developing tools to preserve/augment the activity of BAPs
and favour their optimum utilisation in food systems appear to be yet another prerequisite at
this stage. Human-volunteer-based clinical studies on standard recommendations to im‐
prove the oversight and safety are also required to confirm the likely results obtained at the in
vitro and animal model systems. To conclude, milk BAPs with their multifunctional assets
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appear to offer substantial upcoming prospective for the development of products to sup‐
port health.
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